EDPB Anonymisation Guidelines Reshape Life Sciences Data Practices
Life sciences compliance and privacy teams must reassess data anonymisation protocols now that the EDPB has clarified when health data is truly anonymous versus merely pseudonymised.
The European Data Protection Board has issued new guidelines on anonymisation techniques, with direct implications for pharmaceutical, biotech, and medical device companies handling patient-level data in the EU. The guidance distinguishes anonymisation from pseudonymisation, sets expectations for technical and organisational safeguards, and warns that re-identification risk can render 'anonymised' datasets personal data under the GDPR. Companies relying on anonymised datasets for clinical research, real-world evidence, or cross-border analytics should audit current methodologies, document residual risk assessments, and update data-sharing agreements. The guidelines also affect secondary uses of clinical trial data and biobank materials, where regulators increasingly scrutinise whether true anonymisation has been achieved. In-house counsel should coordinate with privacy officers and data scientists to confirm compliance before the EDPB finalises its position.